Search Result

Results for "

OCI-Ly10

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Apoptosis (7) ATM/ATR (1) Autophagy (1) BCL6 (1) Btk (8) ClpP (1) CRM1 (1) Deubiquitinase (1) E3 Ligase Ligand-Linker Conjugates (1) Ferroptosis (1) Fluorescent Dye (1) HMG Family (1) IFNAR (1) IKZF Family (2) IRAK (5) JAK (1) Ligands for E3 Ligase (1) Malate Dehydrogenase (MDH) (1) MALT1 (1) MDM-2/p53 (1) MMP (1) mTOR (1) NF-κB (3) PERK (1) Phosphatase (1) PROTACs (7) Reactive Oxygen Species (ROS) (2) RSV (1) SHP1 (1) Src (1) STAT (1) Syk (1)
By Research Areas:	Cancer (22) Infection (1) Inflammation/Immunology (3)
Click Chemistry:	PROTAC Synthesis (1)

Inhibitors & Agonists

Peptides

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153368

Zomiradomide KT-413	PROTACs IRAK NF-κB IFNAR	Cancer
Zomiradomide is an orally active PROTAC degrader for IRAK4 (DC₅₀=6 nM), thereby inhibiting the NF-κB signaling pathway. Zomiradomide acts also as a molecular glue, recruiting Ikaros and Aiolos, and mediating their degradation (DC₅₀ for Ikaros is 1 nM), thereby activating the type I IFN signaling pathway . (Pink: target protein ligand PROTAC IRAK4 ligand-5 (HY-168311), Blue: E3 ligase ligand Thalidomide-4-Br (HY-W039116), Black: linker (HY-168313))

HY-W087383

Thalidomide 5-fluoride	Ligands for E3 Ligase Autophagy Apoptosis	Cancer
Thalidomide 5-fluoride is a thalidomide-based Cereblon ligand used to recruit Cereblon protein. Thalidomide 5-fluoride can be linked to target protein ligands (e.g. IRAK4) through a linker to form PROTAC molecules (e.g. PROTAC IRAK4 degrader-1). PROTAC IRAK4 degrader-1 caused <20%, >20-50%, and >50% IRAK4 protein degradation in OCI-LY-10 cells at concentrations of 0.01, 0.1, and 1 μM, respectively .

HY-147791

MDH1-IN-2 1 Publications Verification	Reactive Oxygen Species (ROS) Ferroptosis Malate Dehydrogenase (MDH)	Inflammation/Immunology Cancer
MDH1-IN-2 (Compound 7c) is a selective MDH1 inhibitor, with IC₅₀ values of 2.27 and 27.47 μM for MDH1 and MDH2, respectively. MDH1-IN-2 can reduce the generation of ROS by inhibiting the conversion of 2-Ketoglutaric acid (HY-W013636) to α-Hydroxyglutaric acid (HY-113038B) mediated by MDH1, thereby suppressing 2-Ketoglutaric acid (HY-W013636)-induced ferroptosis .

HY-15970

Verdinexor 2 Publications Verification KPT-335	CRM1 Apoptosis RSV	Infection Inflammation/Immunology Cancer
Verdinexor (KPT-335) is an orally active inhibitor for selective inhibitor of nuclear export (SINE). Verdinexor inhibits the respiratory syncytial virus A2 (RSV A2) replication with an IC₅₀ of 0.96 µM. Verdinexor inhibits the function of nuclear export protein Exportin 1 (XPO1/CRM1), inhibiting pro-inflammatory responses. Verdinexor exhibits antitumor effciency .

HY-159480

AD1058	Src ATM/ATR Apoptosis mTOR AMPK	Cancer
AD1058 is an orally active, selective, and BBB-permeable inhibitor of ATR (IC₅₀: 1.6 nM). AD1058 exhibits anticancer activity by inhibiting tumor cell proliferation, inducing cell cycle arrest, and promoting apoptosis. AD1058 is suitable for research on advanced malignancies and brain metastases .

HY-147943

PROTAC BTK Degrader-1	PROTACs Btk	Cancer
PROTAC BTK Degrader-1 is a potent, selective and orally active PROTAC BTK degrader with an IC₅₀ value of 34.51 nM and 64.56 nM for BTK WT and BTK-481S, respectively. PROTAC BTK Degrader-1 effectively reduces BTK protein levels and suppresses tumor growth . PROTAC BTK Degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-148369

U7D-1	PROTACs Deubiquitinase Apoptosis MDM-2/p53	Cancer
U7D-1 is a first-in-class potent and selective USP7 (ubiquitin-specific protease 7) PROTAC degrader, with a DC₅₀ of 33 nM in RS4;11 cells. U7D-1 shows anticancer activity. U7D-1 induces apoptosis in Jeko-1 cells .

HY-173048

CLPP-2068	ClpP Apoptosis Reactive Oxygen Species (ROS)	Cancer
CLPP-2068 is the orally active activator for human caseinolytic protease P (HsClpP) with an EC₅₀ of 50.4 nM. CLPP-2068 exhibits anti-proliferative efficacy in OCI-LY10 cancer cell with an IC₅₀ of 5.2 nM. CLPP-2068 decreases mitochondrial membrane potential, increases mitochondrial ROS levels, and induces mitochondrial dysfunction. CLPP-2068 arrests the cell cycle at G1 phase, and induces apoptosis in cell OCI-LY10. CLPP-2068 exhibits antitumor activity in mouse xenograft models .

HY-168929

SHP1 activator 1	SHP1 Fluorescent Dye Phosphatase STAT Apoptosis	Cancer
SHP1 activator 1 (Compound 3n) is an activator for src homology-2 domain-containing protein tyrosine phosphatase 1(SHP1) with an EC₅₀ of 17.66 μM. SHP1 activator 1 inhibits the proliferation of ABC-DLBCL cells, induces apoptosis by inhibiting STAT3 signaling pathway. SHP1 activator 1 emitts blue and green fluorescence signalis in MDA-MB-231 cell, and can be used as a cell imaging agent .

HY-150593

IRAK4-IN-16	IRAK	Cancer
IRAK4-IN-16 (compound 4) is a potent IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor, with an IC₅₀ of 2.5 nM. IRAK4-IN-16 shows cytotoxicity activity against OCI-LY10, TMD8, Ramos and HT cells, with IC₅₀ values of 0.2, 0.2, 0.6, and 2.7 μM, respectively .

HY-162407

I-As-1	Btk	Cancer
I-As-1 is a potent inhibitor of Bruton’s tyrosine kinase (BTK), with the IC₅₀ of 2.35 nM. I-As-1 shows antiproliferative activities among Ramos cells and OCI-LY10 cells with IC₅₀s of 0.52 μM and 0.11 μM, respectively .

HY-148275

KTX-955	PROTACs IRAK	Cancer
KTX-955 is an antumor and effective IRAK4 degrader, with DC₅₀ values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively . KTX-955 is composed of CRBN ligand (blue part) Pomalidomide (HY-10984) and target protein ligand (red part) IRAK4-IN-20 (HY-150735).

HY-179077

PROTAC BTK/IKZF1/3 Degrader-1	PROTACs Btk IKZF Family	Cancer
PROTAC BTK/IKZF1/3 Degrader-1 is a selective and orally active BCL6 and IKZF1/3 PROTAC degrader. PROTAC BTK/IKZF1/3 Degrader-1 exhibits antitumor activity. PROTAC BTK/IKZF1/3 Degrader-1 can be used for the research of cancer, such as lymphoma . (Structure Note: Pink: BCL6/IKZF1/3 ligand (HY-179076); Blue: CRBN ligand (HY-41547))

HY-155574

IRAK4-IN-27	IRAK Apoptosis	Cancer
IRAK4-IN-27 (Compound 22) is a potent, selective inhibitor of IRAK4, with IC₅₀ of 8.7 nM. IRAK4-IN-27 inhibits cell growth, and promotes apoptosis in MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line. IRAK4-IN-27 can be used for DLBCL study .

HY-179075

PROTAC BCL6/IKZF1/3 Degrader-1	PROTACs BCL6 IKZF Family	Cancer
PROTAC BCL6/IKZF1/3 Degrader-1 is a selective and orally active BCL6 and IKZF1/3 PROTAC degrader. PROTAC BCL6/IKZF1/3 Degrader-1 exhibits superior antiproliferative effects in various germinal center B-cell-like (GCB) and activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) cell lines. PROTAC BCL6/IKZF1/3 Degrader-1 can be used for the research of cancer, such as lymphoma . (Structure Note: Pink: BCL6/IKZF1/3 ligand (HY-179064); Blue: CRBN ligand (HY-41547); Black: linker (HY-42427); CRBN ligand-Linker: (HY-179066))

HY-150594

IRAK4-IN-17	IRAK NF-κB	Cancer
IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC₅₀ of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .

HY-155072

PROTAC BTK Degrader-5	PROTACs Btk	Cancer
PROTAC BTK degraders-5(compound 3e) is a selective BTK PROTAC degrader with a DC₅₀ value of 7.0 nM in JeKo-1 cells. PROTAC BTK degraders-5 has no off-target effect on degrading CRBN neosubstates. PROTAC BTK degraders-5 has anti-proliferation effect on various lymphoma tumor cells and can be used in chronic lymphoid malignancies research (Blue: E3 ligand (HY-W440230), Black: linker HY-168297；Pink:BKT inhibitor (HY-150898)) ¹.

HY-P4544

Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone	MALT1 NF-κB MMP	Cancer
Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone is an irreversible MALT1 protein inhibitor. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .

HY-147754

JAK3/BTK-IN-6	Btk JAK	Inflammation/Immunology
JAK3/BTK-IN-6 (compound 14h) is a potent BTK and JAK3 dual inhibitor, with IC₅₀ values of 0.6 and 0.4 nM, respectively. JAK3/BTK-IN-6 shows good metabolic stability in human liver microsome. JAK3/BTK-IN-6 can be used for hematological and immune diseases research .

HY-181546

Ibt-DOX	Btk PERK Syk HMG Family	Cancer
Ibt-DOX is a BTK inhibitor with an IC₅₀ of 2.89 nM. Ibt-DOX is also a targeted covalent activated chemotherapeutic agent composed of the targeting ligand Ibrutinib (HY-10997), Doxorubicin (DOX) (HY-15142A), α-MAA (HY-W017180), and a linker (HY-Y0892). Ibt-DOX specifically binds to BTK and releases DOX, synergistically achieving BTK inhibition and chemotherapeutic killing, significantly enhancing toxicity against B-cell lymphoma cells and greatly reducing the toxic side effects of DOX on BTK-negative cells. Ibt-DOX can be used in lymphoma-related research .

HY-181547

HBC-12551	Btk	Cancer
HBC-12551 is an orally active BTK inhibitor (IC₅₀ in HEK293 cells: 1.31 nM for BTK; 2.18 nM for BTK ^C481S). HBC-12551 has antitumor activity against diffuse large B-cell lymphoma .

HY-W017180

2-(Bromomethyl)acrylic acid α-(Bromomethyl)acrylic acid; α-Methylated acrylamide; α-MAA	Btk	Cancer
2-(Bromomethyl) acrylic acid is a Bruton's tyrosine kinase (BTK) inhibitor. 2-(Bromomethyl) acrylic acid forms a covalent bond with the cysteine 481 (Cys481) residue of BTK via a nucleophilic addition-elimination reaction, thereby inhibiting the downstream B-cell receptor signaling pathway. 2-(Bromomethyl) acrylic acid induces immunogenic cell death in BTK-expressing B-cell lymphoma cells by releasing damage-associated molecular patterns including extracellular ATP and HMGB1. 2-(Bromomethyl) acrylic acid exhibits cytotoxicity against BTK-expressing B-cell lymphoma cells, but shows low toxicity to BTK-negative cells. 2-(Bromomethyl) acrylic acid can be used in studies related to B-cell lymphoma .

HY-W1115268

E3 Ligase Ligand-linker Conjugate 231	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 231 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 231 can be used for the synthesis of the PROTAC BRD9 Degrader-8 (HY-162651) .

Cat. No.	Product Name	Target	Research Area

HY-P4544

Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone	MALT1 NF-κB MMP	Cancer
Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone is an irreversible MALT1 protein inhibitor. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .

Cat. No.	Product Name		Classification

HY-147943

PROTAC BTK Degrader-1		PROTAC Synthesis
PROTAC BTK Degrader-1 is a potent, selective and orally active PROTAC BTK degrader with an IC₅₀ value of 34.51 nM and 64.56 nM for BTK WT and BTK-481S, respectively. PROTAC BTK Degrader-1 effectively reduces BTK protein levels and suppresses tumor growth . PROTAC BTK Degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.